Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Common Equity (2013 - 2026)

Scynexis' (SCYX) quarterly Common Equity came in at $66.9 million in Q2 2026, up 50.52% on a YoY basis from $44.5 million in Q2 2025, and up 62.03% quarter-over-quarter from $41.3 million in Q1 2026.

Analysis

Scynexis (SCYX) Common Equity (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Common Equity for 14 consecutive years, with $66.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity rose 50.52% year-over-year to $66.9 million; the trailing twelve-month figure through Jun 2026 stood at $66.9 million (up 50.52% YoY), and the FY2025 full-year result was $49.4 million, down 10.35% from the prior year.
  • Common Equity grew to $66.9 million in Q2 2026 per SCYX's latest filing, from $41.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $150.0 million in Q3 2022 and bottomed at -$29.9 million in Q1 2023.
  • Historically, Common Equity has averaged $55.7 million across 5 years, with a median of $52.8 million in 2024.
  • The widest YoY moves for Common Equity: up 2156.79% in 2023, down 176.85% in 2023.
  • Over 5 years, Common Equity stood at $3.2 million in 2022, then jumped by 2156.79% to $73.0 million in 2023, then fell by 24.51% to $55.1 million in 2024, then declined by 10.35% to $49.4 million in 2025, then jumped by 35.55% to $66.9 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $66.9 million, $41.3 million, and $49.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 8.42 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 4.92 Bn
10 Scynexis 58.41 Mn -56.29 Mn - 66.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 66.93 Mn
Mar 31, 2026 41.31 Mn
Dec 31, 2025 49.38 Mn
Sep 30, 2025 36.43 Mn
Jun 30, 2025 44.47 Mn
Mar 31, 2025 50.53 Mn
Dec 31, 2024 55.08 Mn
Sep 30, 2024 58.53 Mn
Jun 30, 2024 60.41 Mn
Mar 31, 2024 74.11 Mn
Dec 31, 2023 72.96 Mn
Sep 30, 2023 91.99 Mn
Jun 30, 2023 93.08 Mn
Mar 31, 2023 -29.91 Mn
Dec 31, 2022 3.23 Mn
Sep 30, 2022 150.00 Mn
Jun 30, 2022 45.48 Mn
Mar 31, 2022 38.93 Mn
Dec 31, 2021 41.26 Mn
Sep 30, 2021 37.61 Mn